(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 May 2011 (26.05.2011)

PCT

(10) International Publication Number
WO 2011/062562 A1

(51) **International Patent Classification**:
C07K 16/18 (2006.01) *A61K 39/42* (2006.01)

(21) **International Application Number**:
PCT/SG2010/000440

(22) **International Filing Date**:
19 November 2010 (19.11.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/262,906 19 November 2009 (19.11.2009) US
201004457-6 21 June 2010 (21.06.2010) SG

(71) **Applicants** *(for all designated States except US)*: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG). **NATIONAL UNIVERSITY OF SINGAPORE** [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **BERTOLETTI, Antonio** [IT/SG]; Singapore Institute for Clinical Sciences, 30 Medical Drive, Singapore 117609 (SG). **SEETHARAMA, Sastry Konduru** [IN/SG]; Singapore Institute for Clinical Sciences, 30 Medical Drive, Singapore 117609 (SG). **MACARY, Paul Anthony** [GB/SG]; Immunology Program and Department of Microbiology, National University of Singapore, 28 Medical Drive, Singapore 117456 (SG). **CHAN, Soh Ha** [SG/SG]; WHO Centre for Immunology & Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Block MD4, 5 Science Drive 2 Singapore 117597 (SG). **TOO, Chien Tei** [MY/SG]; Immonology Program and Department of Microbiology, National University of Singapore, 28 Medical Drive, Singapore 117456 (SG).

(74) **Agent**: **MOHANAKRISHNAN, Gayathri**; MARKS & CLERK SINGAPORE LLP, Tanjong Pagar, PO Box 636, Singapore 910816 (SG).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*


Published:

— *with international search report (Art. 21(3))*

[Continued on next page]

(54) **Title**: HEPATITIS B VIRUS SPECIFIC ANTIBODY AND USES THEREOF

FIGURE 1



(57) **Abstract**: There is provided at least one isolated TCR-like antibody or fragment thereof, wherein the antibody or fragment thereof is capable of specifically binding to at least one HBV derived peptide.

WO 2011/062562 A1

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*